This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand
by Zacks Equity Research
MMSI beats third-quarter 2025 estimates on strong revenue and margin growth, prompting a raised full-year outlook across segments.
SYK Stock Falls Despite Q3 Earnings & Sales Beat, '25 View Up
by Zacks Equity Research
Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
GEHC vs. ESLOY: Which Stock Is the Better Value Option?
by Zacks Equity Research
GEHC vs. ESLOY: Which Stock Is the Better Value Option?
GE HealthCare (GEHC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for GE HealthCare (GEHC) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls
by Zacks Equity Research
GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.
GE HealthCare Technologies (GEHC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of +1.90% and +1.48%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
by Sridatri Sarkar
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs
by Aparajita Dutta
Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.
GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring
by Zacks Equity Research
GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.
GEHC Stock Up Following New Launch to Streamline Perinatal Workflow
by Zacks Equity Research
GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.
U.S.-China Trade Tensions Stiffen: ETF Areas Likely to Lose the Most
by Sanghamitra Saha
As U.S.-China trade tensions intensify again, ETFs like SMH, XLK, TSLT, BJK, XRT, RTH, LGHT, and USO are likely to come under pressure.
GE Healthcare Partners With Erasmus to Advance Precision Cancer Care
by Zacks Equity Research
GEHC's collaboration with Erasmus MC aims to advance precision oncology using next-gen total body PET/CT and AI imaging innovations.
TEM Expands Partnership With Northwestern Medicine Amid AI Boom
by Sridatri Sarkar
Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
by Sridatri Sarkar
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
How to Play HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic's breast health innovations, AI breakthroughs and leadership moves signal optimism ahead despite macro headwinds.
Can Doximity's New AI Suite Drive the Growth It Needs?
by Indrajit Bandyopadhyay
DOCS reports stronger Q1 results and is betting on its new AI suite -- Scribe, GPT, and Pathway -- to drive its next growth phase.
Top Analyst Reports for IBM, Williams Cos & Hilton Worldwide
by Mark Vickery
IBM, Williams and Hilton Worldwide stand out in new analyst reports highlighting growth drivers, risks, and market performance.
GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent
by Zacks Equity Research
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?
by Moumi Mondal
Hologic set to end sales of Fluoroscan InSight FD in 2025 but sees strong momentum from DXA systems and broader business growth.
Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?
by Zacks Equity Research
Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.
Reasons to Add Labcorp Stock to Your Portfolio Right Now
by Zacks Equity Research
LH's biopharma lab growth and efficiency gains boost momentum, but currency and macro pressures weigh on its outlook.
GEHC or A: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. A: Which Stock Is the Better Value Option?
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
by Zacks Equity Research
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.
GE HealthCare (GEHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
GE HealthCare (GEHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).